• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of thoraxThoraxVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Thorax. Jul 2004; 59(7): 574–580.
PMCID: PMC1747070

Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis

Abstract

Background: Individuals with chronic obstructive pulmonary disease (COPD) are at increased risk of cardiovascular diseases, osteoporosis, and muscle wasting. Systemic inflammation may be involved in the pathogenesis of these disorders. A study was undertaken to determine whether systemic inflammation is present in stable COPD.

Methods: A systematic review was conducted of studies which reported on the relationship between COPD, forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC), and levels of various systemic inflammatory markers: C-reactive protein (CRP), fibrinogen, leucocytes, tumour necrosis factor-α (TNF-α), and interleukins 6 and 8. Where possible the results were pooled together to produce a summary estimate using a random or fixed effects model.

Results: Fourteen original studies were identified. Overall, the standardised mean difference in the CRP level between COPD and control subjects was 0.53 units (95% confidence interval (CI) 0.34 to 0.72). The standardised mean difference in the fibrinogen level was 0.47 units (95% CI 0.29 to 0.65). Circulating leucocytes were also higher in COPD than in control subjects (standardised mean difference 0.44 units (95% CI 0.20 to 0.67)), as were serum TNF-α levels (standardised mean difference 0.59 units (95% CI 0.29 to 0.89)).

Conclusions: Reduced lung function is associated with increased levels of systemic inflammatory markers which may have important pathophysiological and therapeutic implications for subjects with stable COPD.

Full Text

The Full Text of this article is available as a PDF (230K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115–126. [PubMed]
  • Kotler DP. Cachexia. Ann Intern Med. 2000 Oct 17;133(8):622–634. [PubMed]
  • Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999 Aug;45(8 Pt 2):1353–1358. [PubMed]
  • Schünemann HJ, Dorn J, Grant BJ, Winkelstein W, Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000 Sep;118(3):656–664. [PubMed]
  • Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996 Sep 21;313(7059):711–716. [PMC free article] [PubMed]
  • Friedman GD, Klatsky AL, Siegelaub AB. Lung function and risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1976 May 13;294(20):1071–1075. [PubMed]
  • Schols Annemie M W J. Pulmonary cachexia. Int J Cardiol. 2002 Sep;85(1):101–110. [PubMed]
  • Biskobing Diane M. COPD and osteoporosis. Chest. 2002 Feb;121(2):609–620. [PubMed]
  • Agustí AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003 Feb;21(2):347–360. [PubMed]
  • Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998 May 13;279(18):1477–1482. [PubMed]
  • Pradhan Aruna D, Manson JoAnn E, Rossouw Jacques E, Siscovick David S, Mouton Charles P, Rifai Nader, Wallace Robert B, Jackson Rebecca D, Pettinger Mary B, Ridker Paul M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002 Aug 28;288(8):980–987. [PubMed]
  • Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001 Jan;32(1):133–138. [PubMed]
  • Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J. 2003 Nov;22(5):809–814. [PubMed]
  • Curtin François, Altman Douglas G, Elbourne Diana. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Stat Med. 2002 Aug 15;21(15):2131–2144. [PubMed]
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188. [PubMed]
  • Sin Don D, Man S F Paul. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003 Mar 25;107(11):1514–1519. [PubMed]
  • Dentener MA, Creutzberg EC, Schols AM, Mantovani A, van't Veer C, Buurman WA, Wouters EF. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax. 2001 Sep;56(9):721–726. [PMC free article] [PubMed]
  • Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1414–1418. [PubMed]
  • Mannino David M, Ford Earl S, Redd Stephen C. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003 Jun 15;114(9):758–762. [PubMed]
  • Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000 Oct;21(19):1584–1590. [PubMed]
  • Yasuda N, Gotoh K, Minatoguchi S, Asano K, Nishigaki K, Nomura M, Ohno A, Watanabe M, Sano H, Kumada H, et al. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med. 1998 Aug;92(8):993–999. [PubMed]
  • Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996 Aug;51(8):819–824. [PMC free article] [PubMed]
  • Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost. 1994 Sep;72(3):343–346. [PubMed]
  • Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Sep 15;164(6):1008–1011. [PubMed]
  • Engström G, Lind P, Hedblad B, Wollmer P, Stavenow L, Janzon L, Lindgärde F. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002 Nov 12;106(20):2555–2560. [PubMed]
  • Jousilahti P, Salomaa V, Rasi V, Vahtera E. Symptoms of chronic bronchitis, haemostatic factors, and coronary heart disease risk. Atherosclerosis. 1999 Feb;142(2):403–407. [PubMed]
  • Bridges RB, Wyatt RJ, Rehm SR. Effects of smoking on inflammatory mediators and their relationship to pulmonary dysfunction. Eur J Respir Dis Suppl. 1986;146:145–152. [PubMed]
  • James AL, Knuiman MW, Divitini ML, Musk AW, Ryan G, Bartholomew HC. Associations between white blood cell count, lung function, respiratory illness and mortality: the Busselton Health Study. Eur Respir J. 1999 May;13(5):1115–1119. [PubMed]
  • Yeung MC, Buncio AD. Leukocyte count, smoking, and lung function. Am J Med. 1984 Jan;76(1):31–37. [PubMed]
  • de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med. 1996 Feb;153(2):633–637. [PubMed]
  • Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1453–1455. [PubMed]
  • Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H, Kato S, Tomoike H. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1179–1184. [PubMed]
  • Takabatake N, Nakamura H, Abe S, Hino T, Saito H, Yuki H, Kato S, Tomoike H. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1215–1219. [PubMed]
  • Vernooy Juanita H, Kükaycan Mehmet, Jacobs Jan A, Chavannes Niels H, Buurman Wim A, Dentener Mieke A, Wouters Emiel F. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002 Nov 1;166(9):1218–1224. [PubMed]
  • Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256–1276. [PubMed]
  • van Eeden SF, Tan WC, Suwa T, Mukae H, Terashima T, Fujii T, Qui D, Vincent R, Hogg JC. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med. 2001 Sep 1;164(5):826–830. [PubMed]
  • Fujii Takeshi, Hayashi Shizu, Hogg James C, Mukae Hiroshi, Suwa Tatsushi, Goto Yukinobu, Vincent Renaud, van Eeden Stephan F. Interaction of alveolar macrophages and airway epithelial cells following exposure to particulate matter produces mediators that stimulate the bone marrow. Am J Respir Cell Mol Biol. 2002 Jul;27(1):34–41. [PubMed]
  • Tan WC, Qiu D, Liam BL, Ng TP, Lee SH, van Eeden SF, D'Yachkova Y, Hogg JC. The human bone marrow response to acute air pollution caused by forest fires. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1213–1217. [PubMed]
  • Salvi S, Blomberg A, Rudell B, Kelly F, Sandström T, Holgate ST, Frew A. Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. Am J Respir Crit Care Med. 1999 Mar;159(3):702–709. [PubMed]
  • Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000 Jul 27;343(4):269–280. [PubMed]
  • Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Jr, Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497–1505. [PubMed]
  • Camilli AE, Robbins DR, Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol. 1991 Apr 15;133(8):795–800. [PubMed]
  • Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000 Aug;84(2):210–215. [PubMed]
  • Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000 Feb;148(2):209–214. [PubMed]
  • Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001 Nov 7;286(17):2107–2113. [PubMed]
  • Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000 Apr 18;101(15):1767–1772. [PubMed]
  • Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003 Oct;22(4):672–688. [PubMed]
  • Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 Feb 11;340(6):448–454. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...